Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Astellas Pharma (JP:4503) has released an update. Astellas Pharma has received FDA approval for VYLOY, a novel treatment targeting CLDN18.2 for ...

Astellas Pharma has gained approval from the US Food and Drug Administration (FDA) for VYLOY (zolbetuximab-clzb), in ...

Bernstein analyst Miki Sogi assigned a Buy rating to Astellas Pharma (ALPMF – Research Report) today and set a price target of ...

The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only ...

Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

The US Food and Drug Administration has approved Vyloy (zolbetuximab-clzb), a claudin 18.2 (CLDN18.2)-directed cytolytic ...

The FDA has simultaneously granted approval to Astellas’ cancer drug Vyloy and to a companion diagnostic test developed by ...

Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...